AIM ImmunoTech Business Summary

AIM ImmunoTech Inc. (AIM) is a clinical-stage biopharmaceutical company that generates revenue primarily through the commercial sale of its flagship products, Ampligen (rintatolimod) and Alferon N Injection, alongside strategic capital raises such as its February 2026 $12 million rights offering. The company operates through a single primary business segment focused on the research and development of double-stranded RNA (dsRNA) therapeutics. Its core asset, Ampligen, is a first-in-class TLR3 agonist being evaluated in high-value clinical programs for late-stage pancreatic cancer, including the DURIPANC study in collaboration with AstraZeneca, as well as treatments for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Long COVID. AIM competes directly with immuno-oncology and antiviral firms such as ImmunityBio, Immunocore Holdings, and Ayala Pharmaceuticals. Within this competitive landscape, AIM occupies a high-risk, high-reward niche as a micro-cap developer of specialized dsRNA-based immunomodulators targeting orphan-status unmet medical needs. Leadership is spearheaded by Chief Executive Officer and President Thomas K. Equels, M.S., J.D., a seasoned executive with over 30 years of experience in pharmaceutical law and distressed company turnarounds. The executive suite includes Chief Financial Officer Robert Dickey IV, who brings 25 years of life science C-suite experience, and Chief Operating Officer Peter W. Rodino III, J.D., who oversees governmental relations and legal strategy. The Board of Directors is chaired by Dr. William M. Mitchell, a Professor of Pathology at Vanderbilt University with over 200 published papers in immunology. Notable board members include newly elected investment veteran Ted D. Kellner, founder of Fiduciary Management, and David I. Chemerow, former CFO of Comscore. The company maintains institutional backing from investors such as Armistice Capital LLC and Sabby Management LLC, reflecting a leadership team deeply rooted in academic medicine, specialized litigation, and biotech financial restructuring.